On November 15, 2022,CG Oncology, Inc. closed the transaction. The company received $119,999,990 million in oversubscribed round of funding co-led by new investor Longitude Capital Management Co., LLC, returning investor ORI Capital and Decheng Capital LLC. The transaction included participation from returning investor Ally Bridge Group, also included RA Capital Management, L.P., Acorn Bioventures, Malin Corporation plc, and Sirona Capital Pty Ltd, Investment Arm.

As a part of the transaction Brian Liu of Longitude Capital Management Co., LLC joined board seat. The company has raised $200 million in funding till date.